Analyst Price Target is $8.00
▼ -23.81% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Checkmate Pharmaceuticals in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a -23.81% upside from the last price of $10.50.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Checkmate Pharmaceuticals.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.